Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French

J M Riedinger1, N Eche, J P Basuyau

  • 1Laboratoire de Biologie Médicale, Centre Georges François Leclerc, 1 rue du Pr Marion, 21034 Dijon cedex, France. jriedinger@dijon.fnclcc.fr

Gynecologic Oncology
|March 11, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cellular interactions of functionalized superparamagnetic iron oxide nanoparticles on oligodendrocytes without detrimental side effects: Cell death induction, oxidative stress and inflammation.

Colloids and surfaces. B, Biointerfaces·2018
Same author

Dual effect of docosahexaenoic acid (attenuation or amplification) on C22:0-, C24:0-, and C26:0-induced mitochondrial dysfunctions and oxidative stress on human neuronal SK-N-BE cells.

The journal of nutrition, health & aging·2015
Same author

A step towards cinacalcet testing for the diagnosis of primary hyperparathyroidism: comparison with the standardized intravenous calcium loading. A pilot study.

Clinical endocrinology·2015
Same author

Glucose-induced incretin hormone release and insulin sensitivity are impaired in patients with idiopathic gastroparesis: results from a pilot descriptive study.

Neurogastroenterology and motility·2013
Same author

Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Cross-reactivity with endogenous proBNP from heart failure patients for three commercial BNP immunoassays.

Clinica chimica acta; international journal of clinical chemistry·2011
Same journal

Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data.

Gynecologic oncology·2026
Same journal

Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia.

Gynecologic oncology·2026
Same journal

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Gynecologic oncology·2026
Same journal

PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy.

Gynecologic oncology·2026
Same journal

A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer.

Gynecologic oncology·2026
Same journal

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026
See all related articles

CA 125 kinetics during chemotherapy offer prognostic insights for ovarian cancer patients. A bi-exponential decrease in CA 125 levels indicates a poor prognosis, guiding treatment strategies.

Area of Science:

  • Oncology
  • Biochemistry
  • Clinical Research

Background:

  • CA 125 assays are crucial for monitoring treatment response in ovarian cancer patients.
  • Understanding CA 125 kinetics provides deeper insights into treatment efficacy.

Purpose of the Study:

  • To evaluate the prognostic value of CA 125 kinetics during first-line paclitaxel/platinum chemotherapy in advanced ovarian cancer.
  • To investigate the clinical implications of CA 125 bi-exponential decrease.

Main Methods:

  • A multicentric study involving 130 patients with stage IIc-IV ovarian cancer receiving paclitaxel/platinum chemotherapy.
  • Analysis of CA 125 half-life, nadir concentration, and decay patterns (mono-exponential vs. bi-exponential).
  • Survival analyses (DFS and OS) using Kaplan-Meier and Cox regression models.

Related Experiment Videos

Main Results:

  • CA 125 nadir concentration, residual tumor volume, and chemotherapy course number were independent prognostic factors for DFS and OS.
  • CA 125 kinetics groups were prognostic for DFS and, notably, for OS when nadir was excluded from the model.
  • A bi-exponential CA 125 decrease was observed in 29.2% of patients and associated with poorer outcomes.

Conclusions:

  • CA 125 kinetics during first-line chemotherapy possess significant and independent prognostic value in ovarian cancer.
  • A bi-exponential CA 125 decrease serves as a specific indicator of poor prognosis.
  • These findings can aid in refining prognostic assessments and treatment decisions for ovarian cancer.